1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY, CA
Ex-99.1
Amendment to Exclusive Option and License Agreement with Hansoh
Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Announces Pricing of Upsized $650 Million Public Offering
Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
Financial Results, Press Release
Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML
Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist in Obesity
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload